当前位置:首页 > 报告详情

TransMedics J.P. Morgan 2026 Presentation.pdf

上传人: 明**** 编号:1069816 2026-01-17 23页 2.84MB

1、Waleed Hassanein,MDPresident&CEO January 2026Establishing the New Standard of Care for Organ Transplantation 2Cautionary Note Regarding Forward Looking Statements This presentation contains forward-looking statements.These forward-looking statements address various matters,including,among other thin

2、gs,future results and events,including growth initiatives and strategies,including potential timelines for products,services,and future product and services candidates,and those relating to the companys product clinical indications,clinical program goals,clinical trials,clinical and regulatory timel

3、ines,the companys Italy NOP plans,potential growth opportunities,and other statements that are predictive in nature.For this purpose,all statements other than statements of historical facts are forward-looking statements.The words believe,may,will,estimate,continue,anticipate,intend,expect,should,co

4、uld,target,predict,seek and similar expressions are intended to identify forward-looking statements.These forward-looking statements are subject to a number of risks and uncertainties.Our management cannot predict all risks,nor can we assess the impact of all factors or the extent to which any facto

5、r,or combination of factors,may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make.In light of these risks and uncertainties,the forward-looking events and circumstances discussed in this presentation may not occur and actual re

6、sults could differ materially and adversely from those anticipated in or implied by the forward-looking statements.Some of the key factors that could cause actual results to differ include:the fluctuation of our financial results from quarter to quarter;our ability to attract,train,and retain key pe

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **公司愿景**:TransMedics致力于建立器官移植护理新标准,通过OCS(器官护理系统)技术解决冷储存局限性,减少缺血损伤并优化器官功能。 2. **核心数据**: - NOP(国家器官采购计划)推动美国DCD(心脏死亡捐献) donors增长533%(2022-2024); - OCS移植利用率达98%(肝脏)、97%(心脏)、96%(肺部); - 2025年前三季度营收同比增长39%,现金储备4.66亿美元。 3. **技术优势**:OCS是唯一多器官便携式温灌注平台,支持实时评估与器官优化,临床证据覆盖DBD(脑死亡捐献)和DCD器官。 4. **增长战略**:2026-2029年目标移植量超2万例,推进新一代心脏/肺OCS临床试验及欧盟NOP扩展。
**OCS技术优势?** **NOP如何提升移植量?** **未来增长策略?**
客服
商务合作
小程序
服务号
折叠